Document is current
Any future updates will be listed below
-
Authors
Boncimino, Fabiana
D’Auria, Ludovica
Todorova, Kristina
van der Zanden, Sabina Y.
Neefjes, Jacques https://orcid.org/0000-0001-6763-2211
Mandinova, Anna https://orcid.org/0000-0001-9273-0972
Missero, Caterina https://orcid.org/0000-0003-0905-5123
Sol, Stefano https://orcid.org/0000-0003-2576-0156
-
Funding
Funding for this research was provided by:
Fondazione Telethon (GGP20124)
- License Information
-
More Information
Article History
Received: 22 October 2024
Revised: 24 December 2024
Accepted: 16 January 2025
First Online: 25 January 2025
Competing interests
: The authors declare the following financial interests, which may be considered potential competing interests: AM is a co-founder (with equity) of New Frontier Bio, a consumer health company developing skincare and anti-aging products, and has equity in DermBiont, a private company advancing targeted topical therapeutics for dermatologic indications. AM, KT, FB and SS receive research support from Shiseido Inc. KT has a financial interest in New Frontier Bio. JN is a shareholder in NIHM, which aims to produce aclarubicin for clinical use. LD, SYvdZ and CM declare no competing interests.
: All methods were performed in accordance with the relevant guidelines and regulations. Approval has been obtained from the animal ethic committee at CEINGE and has been approved by the Italian Ministry of Health under the animal license 311/2016-PR. This study does not involve human subjects.
